These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35422411)

  • 1. Presentation and Impact of Double and Triple hit Cytogenetics in Patients With Multiple Myeloma in the Real World.
    Singh C; Panakkal V; Sreedharanunni S; Jandial A; Jain A; Lad D; Prakash G; Khadwal A; Malhotra P
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e685-e690. PubMed ID: 35422411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Features and Outcomes of Patients with Double-Hit/Triple-Hit Multiple Myeloma Detected at Relapse.
    Singh C; Panakkal V; Sreedharanunni S; Jandial A; Jain A; Lad D; Prakash G; Khadwal A; Malhotra P
    Indian J Hematol Blood Transfus; 2023 Jan; 39(1):151-153. PubMed ID: 36699422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].
    Liu XL; Yang YP; Bai J; Yue TT; Yang PY; Zhang Y; Fan HQ; Li W; Jin FY
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):912-917. PubMed ID: 31856439
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cytogenetic Abnormalities and Outcomes of 117 Patients with Multiple Myeloma Detected by FISH].
    Zhai B; Zou DD; Yan JJ; Wang N; Wang LL; Zhu HL; Huang WR; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):127-30. PubMed ID: 26913408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Epidemiological analysis of cytogenetic abnormalities in patients with newly-diagnosed multiple myeloma: a multi-center retrospective study].
    Yuan RF; Dong YJ; Li CR; Huang WR; Zhang LM; Zhu Q; Xu L; Xu YJ; Xu Q; Gao GX; Jin FY
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jan; 41(1):10-15. PubMed ID: 32023748
    [No Abstract]   [Full Text] [Related]  

  • 6. The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse.
    Wang Y; Xu J; Xu B; Li P; Yang Y; Wang W; Xu T; Maihemaiti A; Lan T; Wang P; Ren L; Zhou C; Aihemaiti X; Liu P
    Cancer; 2023 Apr; 129(7):1005-1016. PubMed ID: 36704927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic analysis of 182 newly diagnosed multiple myeloma patients with high risk cytogenetic abnormalities].
    Liu XL; Bai J; Fan HQ; Yang YP; Yue TT; Zhang Y; Yang PY; Gao SJ; Li W; Jin FY
    Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):644-649. PubMed ID: 31495130
    [No Abstract]   [Full Text] [Related]  

  • 8. Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance.
    Baysal M; Demirci U; Umit E; Kirkizlar HO; Atli EI; Gurkan H; Gulsaran SK; Bas V; Mail C; Demir AM
    Sci Rep; 2020 Apr; 10(1):5991. PubMed ID: 32249811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma.
    Uryu H; Mishima Y; Ishihara Y; Shirouchi Y; Yamauchi N; Hirano M; Hirano K; Teramoto Y; Yoshida K; Maruyama D
    J Clin Exp Hematop; 2024; 64(1):10-20. PubMed ID: 38538316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The frequency and clinical outcome of mono-hit and multi-hit TP53 aberrations in newly diagnosed multiple myeloma.
    Sreedharanunni S; Singla S; Balakrishnan A; Singh A; Jamwal M; Singh N; Singh C; Jandial A; Lad D; Sharma P; Sachdeva MUS; Malhotra P; Das R
    Pathology; 2024 Jun; 56(4):556-564. PubMed ID: 38413253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805).
    Kim K; Kim JS; Yoon SS; Yoon DH; Eom HS; Lee JJ; Yim HW; Park M; Lee H; Min CK;
    Int J Hematol; 2022 Jul; 116(1):110-121. PubMed ID: 35543899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of hyperdiploidy in multiple myeloma patients with high-risk cytogenetics: a pilot study in China.
    Mei J; Zhai Y; Li H; Li F; Zhou X; Song P; Zhao Q; Yu Y; An Z; Wang L
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2263-2273. PubMed ID: 30167888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
    Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization results.
    Harrison CJ; Mazzullo H; Cheung KL; Gerrard G; Jalali GR; Mehta A; Osier DG; Orchard KH
    Br J Haematol; 2003 Mar; 120(6):944-52. PubMed ID: 12648063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation.
    Greslikova H; Zaoralova R; Filkova H; Nemec P; Oltova A; Kupska R; Rudolecka P; Smetana J; Pour L; Zahradova L; Krejci M; Buchler T; Adam Z; Hajek R; Kuglik P
    Neoplasma; 2010; 57(2):111-7. PubMed ID: 20099973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.
    Nemec P; Zemanova Z; Kuglik P; Michalova K; Tajtlova J; Kaisarova P; Oltova A; Filkova H; Holzerova M; Balcarkova J; Jarosova M; Rabasova J; Hruba M; Spicka I; Gregora E; Adam Z; Scudla V; Maisnar V; Schutzova M; Hajek R;
    Leuk Lymphoma; 2012 May; 53(5):920-7. PubMed ID: 22023516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma.
    Hao S; Lu X; Gong Z; Bassett RL; Hu S; Konoplev SN; Tang G; Li S; Xu J; Khanlari M; Lee HC; Manasanch EE; Weber DM; Orlowski RZ; Medeiros LJ; Lin P
    Mod Pathol; 2021 Feb; 34(2):327-335. PubMed ID: 32908255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Utility of a Diagnostic Approach to Detect Genetic Abnormalities in Multiple Myeloma: A Single Institution Experience.
    Jung HA; Jang MA; Kim K; Kim SH
    Ann Lab Med; 2018 May; 38(3):196-203. PubMed ID: 29401553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.
    Varma A; Sui D; Milton DR; Tang G; Saini N; Hasan O; Mukherjee A; Joseph JJ; Bashir Q; Rondon G; Srour S; Popat UR; Hosing CM; Nieto Y; Kebriaei P; Alousi AM; Ahmed S; Mehta R; Khouri IF; Ahmed H; Iyer S; Weber DM; Thomas SK; Manasanch E; Lee HC; Patel K; Ciurea SO; Shpall EJ; Orlowski RZ; Champlin RE; Qazilbash MH
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):665-671. PubMed ID: 31881283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.